BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Fudotinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Fudotinib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07154368-2440@assetmemo.bio
DTSTAMP:20261121T004529Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Fudotinib: Phase 3 readout est. (NCT07154368)
DESCRIPTION:Fudotinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: JYP03
 22 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Pr
 eviously Treated With ROS1-TKIs.\nEstimated primary completion: 31 October
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/fudotinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07154368
URL:https://assetmemo.bio/drug/fudotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816380-2440@assetmemo.bio
DTSTAMP:20261121T004529Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Fudotinib: Phase 3 readout est. (NCT07816380)
DESCRIPTION:Fudotinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously 
 Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung
  Cancer\nEstimated primary completion: 30 December 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/fudotinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07816380
URL:https://assetmemo.bio/drug/fudotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
